Etanercept · people with chronic plaque psoriasis
Any systemic treatment probably leads to higher etanercept compared with placebo (moderate certainty).
2 findings from 1 review
Tofacitinib · people with chronic plaque psoriasis
Any systemic treatment may leads to higher tofacitinib compared with placebo (low certainty).
2 findings from 1 review
Apremilast · people with chronic plaque psoriasis
Any systemic treatment probably leads to higher apremilast compared with placebo (moderate certainty).
2 findings from 1 review
Fumaric acid · people with chronic plaque psoriasis
It is very uncertain whether any systemic treatment changes fumaric acid compared with placebo (very low certainty).
1 finding from 1 review
Acitretin · people with chronic plaque psoriasis
It is very uncertain whether any systemic treatment changes acitretin compared with placebo (very low certainty).
2 findings from 1 review
Ixekizumab · people with chronic plaque psoriasis
Any systemic treatment probably leads to higher ixekizumab compared with placebo (moderate certainty).
2 findings from 1 review
Bimekizumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in bimekizumab compared with placebo (low certainty).
2 findings from 1 review
Risankizumab · people with chronic plaque psoriasis
Any systemic treatment probably leads to lower risankizumab compared with placebo (moderate certainty).
2 findings from 1 review
Ustekinumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in ustekinumab compared with placebo (moderate certainty).
2 findings from 1 review
Fumaric acid esters · people with chronic plaque psoriasis
It is very uncertain whether any systemic treatment changes fumaric acid esters compared with placebo (very low certainty).
1 finding from 1 review
Guselkumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in guselkumab compared with placebo (moderate certainty).
2 findings from 1 review
Adalimumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in adalimumab compared with placebo (moderate certainty).
2 findings from 1 review
Brodalumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in brodalumab compared with placebo (moderate certainty).
2 findings from 1 review
Secukinumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in secukinumab compared with placebo (moderate certainty).
2 findings from 1 review
Functional success, defined as the relief of epiphora · nasolacrimal duct obstruction
Mitomycin C dacryocystorhinostomy showed no clear difference in functional success, defined as the relief of epiphora compared with dacryocystorhinostomy alone (low certainty).
2 findings from 1 review
Anatomic success, defined as patency to lacrimal irrigation · nasolacrimal duct obstruction
Mitomycin C dacryocystorhinostomy showed no clear difference in anatomic success, defined as patency to lacrimal irrigation compared with dacryocystorhinostomy alone (low certainty).
2 findings from 1 review
Ostium size on nasal endoscopy · nasolacrimal duct obstruction
Mitomycin C dacryocystorhinostomy showed no clear difference in ostium size on nasal endoscopy compared with dacryocystorhinostomy alone (low certainty).
2 findings from 1 review
Intervention not reported
Overall survival · Individuals with Hodgkin lymphoma
The intervention probably leads to higher overall survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival · Individuals with Hodgkin lymphoma
It is very uncertain whether the intervention changes progression‐free survival (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events associated with PET ‐ not reported · Individuals with Hodgkin lymphoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found